Skip to main content

Table 5 Overall survival analysis of metastatic breast cancer patients, showing the p value, hazard ratio and the 95% confidence interval for this hazard ratio. Stratified or normalized continuous biomarkers used as variables. Univariate and multivariate analysis

From: Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer

Variable

p value

Hazard ratio

95% CI for HR

Type of analysis

Type of variable

Lower

Upper

Overall survival analysis

 CTC threshold

< 0.0001

2.870

1.876

4.392

Univariate

Stratified biomarker

 cfDNA threshold

< 0.0001

2.296

1.476

3.570

 CA15-3 threshold

< 0.0001

2.876

1.717

4.816

 AP threshold

< 0.0001

3.063

1.982

4.732

 CTC threshold

0.162

1.447

0.862

2.430

*Multivariate

 cfDNA threshold

0.034

1.684

1.041

2.726

 CA15-3 threshold

0.017

1.973

1.130

3.446

 AP threshold

0.006

1.996

1.219

3.268

 CTC count

0.003

1.213

1.068

1.376

Univariate

Normalized continuous biomarker

 cfDNA yield

0.016

1.216

1.037

1.427

 CA15-3 levels

0.001

1.278

1.110

1.472

 AP levels

< 0.0001

1.611

1.365

1.902

 CTC count

0.001

1.243

1.088

1.421

*Multivariate

 cfDNA yield

0.024

1.199

1.024

1.405

 CA15-3 levels

0.168

1.120

0.953

1.315

 AP levels

< 0.0001

1.565

1.307

1.874

  1. *Multivariate analysis represent the combination and analysis of all biomarkers (CTC count, cfDNA yield, CA15-3 levels and AP levels) together, as a joint analysis, to explore the possible interactions between them and how this interactions affects their effect on the clinical variables under study